Exudative Macular Degeneration Clinical Trial
Official title:
Intravitreal Tissue Plasminogen Activator And Perfluoropropane for Neovascular Age-related Macular Degeneration With Associated Submacular Haemorrhage: a Multi-centre, Randomized, Double-masked, Sham-controlled, Factorial, Feasibility Study
This study will recruit patients who have recently had a submacular haemorrhage (bleed under
the part of the retina responsible for detailed vision), as a complication of wet age-related
macular degeneration (wet AMD). Wet AMD is a very common disease where abnormal blood vessels
form under the retina and leak, causing a significant reduction in vision.
The study will investigate treatment of the bleed with various combinations of the two drugs:
tissue plasminogen activator (tPA) - designed to dissolve the blood clot; and
perfluoropropane (C3F8) - designed to shift the blood clot away from the central part of the
retina (the macula). tPA is a commonly used 'clot-buster' drug for the treatment of stroke.
C3F8 is a gas commonly used in eye surgery. Patients recruited will be divided into four
groups: control group that receive none of the above drugs; one group that receives only tPA;
one group that receives only C3F8; and one group that receives both.
All patients will receive the current gold standard treatment for wet AMD, ranibizumab
(Lucentis®).
The aim of the study is to improve vision in a condition, which left untreated, would cause
severe visual loss.
Age-related macular degeneration (AMD) is the commonest cause of blindness worldwide. Its
prevalence increases with age, being relatively rare under 60 years and reaching its peak
incidence in those older than 80 years. AMD principally affects central vision, which is
responsible for the ability to see fine detail and the disease rapidly destroys the ability
to read normal print, recognise faces, drive, and watch television. It can therefore have a
profound effect on quality of life.
There are two main forms of AMD; the dry form, in which there is slow degeneration of the
cells responsible for sight, resulting in gradual visual loss; and the wet form
(neovascular), which occurs when abnormal blood vessels (choroidal neovascularisation) grow
under the retina, the part of the eye which is responsible for sensing light, like the film
of a camera. These new blood vessels have weak walls leading to leakage of fluid (oedema),
and sometimes significant amounts of bleeding (submacular haemorrhage - SMH). These rapidly
lead to central visual distortion and blurring. Although the dry form is commoner, the wet
form more commonly results in profound central visual loss and is responsible for the
majority of cases that ultimately require blind registration.
The current best treatment ('gold-standard') for wet AMD is the drug ranibizumab (Lucentis®),
which aims to shrink and destroy the abnormal blood vessels responsible for the visual
symptoms. In several trials ranibizumab has been shown to improve vision in patients with wet
AMD.
It is not uncommon for patients with wet AMD to develop SMH, which when it occurs,
significantly reduces the patient's visual prognosis. SMH is thought to have a number of
toxic consequences on the retinal function.
This study investigates the use of two drugs: tissue plasminogen activator (tPA), a
'clot-buster' drug used to treat stroke, which is designed to dissolve the clot over the
central retina (macula); and perfluoropropane (C3F8), a gas commonly used in retinal surgery,
which is designed to displace the clot away from the macula.
This study is a randomized, double-masked, clinical trial with a recruitment target of 55
people with SMH and wet AMD. Participants will be allocated to one of four groups; a control
group receiving none of the above drugs; one group receiving only tPA; one group receiving
only C3F8; and one group receiving both. All patients will receive the 'gold-standard'
treatment of ranibizumab for their underlying wet AMD. We aim to determine if tPA and/or C3F8
produce a visual outcome that is superior to standard care, with a favourable safety profile.
We will also measure the size of the blood clot and scarring using computer analysis of
macula photographs.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01674569 -
Pilot Study of X-82 in Patients With Wet AMD
|
Phase 1/Phase 2 | |
Recruiting |
NCT04504123 -
MMP-9 Inhibition for Recalcitrant Wet AMD
|
Phase 2 | |
Completed |
NCT01473251 -
Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration
|
N/A | |
Recruiting |
NCT05093374 -
Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
|
Phase 4 | |
Completed |
NCT01617148 -
Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
|
Phase 4 | |
Completed |
NCT01535950 -
Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)
|
Phase 2 | |
Completed |
NCT02287298 -
Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment
|
N/A | |
Active, not recruiting |
NCT03803631 -
CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)
|